249 related articles for article (PubMed ID: 16042805)
1. Gait dynamics in mouse models of Parkinson's disease and Huntington's disease.
Amende I; Kale A; McCue S; Glazier S; Morgan JP; Hampton TG
J Neuroeng Rehabil; 2005 Jul; 2():20. PubMed ID: 16042805
[TBL] [Abstract][Full Text] [Related]
2. Treadmill gait analysis does not detect motor deficits in animal models of Parkinson's disease or amyotrophic lateral sclerosis.
Guillot TS; Asress SA; Richardson JR; Glass JD; Miller GW
J Mot Behav; 2008 Nov; 40(6):568-77. PubMed ID: 18980909
[TBL] [Abstract][Full Text] [Related]
3. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease.
Hausdorff JM; Cudkowicz ME; Firtion R; Wei JY; Goldberger AL
Mov Disord; 1998 May; 13(3):428-37. PubMed ID: 9613733
[TBL] [Abstract][Full Text] [Related]
4. A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty.
Kurz MJ; Pothakos K; Jamaluddin S; Scott-Pandorf M; Arellano C; Lau YS
Neurosci Lett; 2007 Dec; 429(1):39-42. PubMed ID: 17977658
[TBL] [Abstract][Full Text] [Related]
5. Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis.
Hausdorff JM; Lertratanakul A; Cudkowicz ME; Peterson AL; Kaliton D; Goldberger AL
J Appl Physiol (1985); 2000 Jun; 88(6):2045-53. PubMed ID: 10846017
[TBL] [Abstract][Full Text] [Related]
6. Treadmill gait analysis characterizes gait alterations in Parkinson's disease and amyotrophic lateral sclerosis mouse models.
Hampton TG; Amende I
J Mot Behav; 2010; 42(1):1-4. PubMed ID: 19906638
[TBL] [Abstract][Full Text] [Related]
7. Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning.
Goldberg NR; Hampton T; McCue S; Kale A; Meshul CK
J Neurosci Res; 2011 Oct; 89(10):1698-706. PubMed ID: 21748776
[TBL] [Abstract][Full Text] [Related]
8. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Kim ST; Son HJ; Choi JH; Ji IJ; Hwang O
Brain Res; 2010 Jan; 1306():176-83. PubMed ID: 19804765
[TBL] [Abstract][Full Text] [Related]
9. Ethanol's effects on gait dynamics in mice investigated by ventral plane videography.
Kale A; Amende I; Meyer GP; Crabbe JC; Hampton TG
Alcohol Clin Exp Res; 2004 Dec; 28(12):1839-48. PubMed ID: 15608600
[TBL] [Abstract][Full Text] [Related]
10. Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
Zhao Q; Cai D; Bai Y
Int J Mol Med; 2013 Oct; 32(4):883-91. PubMed ID: 23877198
[TBL] [Abstract][Full Text] [Related]
11. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo.
Yang L; Sugama S; Mischak RP; Kiaei M; Bizat N; Brouillet E; Joh TH; Beal MF
Neurobiol Dis; 2004 Nov; 17(2):250-9. PubMed ID: 15474362
[TBL] [Abstract][Full Text] [Related]
12. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Tasaki Y; Yamamoto J; Omura T; Sakaguchi T; Kimura N; Ohtaki K; Ono T; Suno M; Asari M; Ohkubo T; Noda T; Awaya T; Shimizu K; Matsubara K
Neurosci Lett; 2012 Jul; 521(1):15-9. PubMed ID: 22617635
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of creatine.
Beal MF
Amino Acids; 2011 May; 40(5):1305-13. PubMed ID: 21448659
[TBL] [Abstract][Full Text] [Related]
14. Pain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Park J; Lim CS; Seo H; Park CA; Zhuo M; Kaang BK; Lee K
Mol Pain; 2015 May; 11():28. PubMed ID: 25981600
[TBL] [Abstract][Full Text] [Related]
15. A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities.
Yang L; Calingasan NY; Chen J; Ley JJ; Becker DA; Beal MF
Exp Neurol; 2005 Jan; 191(1):86-93. PubMed ID: 15589515
[TBL] [Abstract][Full Text] [Related]
16. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
17. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.
Diguet E; Fernagut PO; Wei X; Du Y; Rouland R; Gross C; Bezard E; Tison F
Eur J Neurosci; 2004 Jun; 19(12):3266-76. PubMed ID: 15217383
[TBL] [Abstract][Full Text] [Related]
18. A novel biomechanical analysis of gait changes in the MPTP mouse model of Parkinson's disease.
Geldenhuys WJ; Guseman TL; Pienaar IS; Dluzen DE; Young JW
PeerJ; 2015; 3():e1175. PubMed ID: 26339553
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
Kanagaraj N; Beiping H; Dheen ST; Tay SS
Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
[TBL] [Abstract][Full Text] [Related]
20. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
